Arcutis Biotherapeutics, Inc.
ARQT
Rankning i aktier
#3977
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aktiekurs
$32.88
Senast synkroniserad: 2026-10-20
Marknadsvärde
$4.13B
Förändring (1 dag)
3.11%
Förändring (1 år)
59.32%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
Antal utestående aktier för Arcutis Biotherapeutics, Inc. (ARQT)
Antal utestående aktier per June 2026: 130.52M
Enligt de senaste finansiella rapporterna och aktiekursen för Arcutis Biotherapeutics, Inc. är det aktuella antalet utestående aktier 130.52M. I slutet av December 2023 hade företaget 69.31M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Arcutis Biotherapeutics, Inc. (ARQT) från 2017 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 130.52M | 7.91% |
| 2024 | 120.96M | 74.53% |
| 2023 | 69.31M | 25.94% |
| 2022 | 55.03M | 11.39% |
| 2021 | 49.41M | 38.52% |
| 2020 | 35.67M | -6.36% |
| 2019 | 38.09M | 5.11% |
| 2018 | 36.24M | 3,331.44% |
| 2017 | 1.06M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 94.53% |
US
|
|
| 396.00M | 203.40% |
US
|
|
| 478.91M | 266.92% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.36% |
NL
|
